{"organizations": [], "uuid": "95703e7b8412551ac9336872d832889cf1e6d148", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180403.html", "section_title": "Archive News &amp; Video for Tuesday, 03 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-allergan-and-richter-say-bipolar-i/brief-allergan-and-richter-say-bipolar-i-depression-study-meets-main-goal-idUSFWN1RG0JY", "country": "US", "domain_rank": 408, "title": "BRIEF-Allergan And Richter Say Bipolar I Depression Study Meets Main Goal", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.793, "site_type": "news", "published": "2018-04-03T20:21:00.000+03:00", "replies_count": 0, "uuid": "95703e7b8412551ac9336872d832889cf1e6d148"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-allergan-and-richter-say-bipolar-i/brief-allergan-and-richter-say-bipolar-i-depression-study-meets-main-goal-idUSFWN1RG0JY", "ord_in_thread": 0, "title": "BRIEF-Allergan And Richter Say Bipolar I Depression Study Meets Main Goal", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "allergan", "sentiment": "negative"}, {"name": "allergan plc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 3 (Reuters) - Allergan Plc - For Rgh-Md :\n* ALLERGAN AND RICHTER ANNOUNCE POSITIVE TOPLINE RESULTS FROM THIRD OF THREE PIVOTAL TRIALS OF CARIPRAZINE IN BIPOLAR I DEPRESSION\n* PRIMARY ENDPOINT WAS MET IN STUDY EVALUATING PATIENTS WITH ACUTE BIPOLAR I DEPRESSION TREATED WITH CARIPRAZINE 1.5 MG VERSUS PLACEBO\n* CARIPRAZINE WAS GENERALLY WELL TOLERATED IN TRIAL * PLANS TO INCLUDE DATA FROM ALL THREE PIVOTAL TRIALS IN COâ€™S SNDA TO U.S. FDA IN SECOND HALF OF 2018\n* MOST COMMONLY REPORTED ADVERSE EVENTS IN CARIPRAZINE GROUPS WERE AKATHISIA, RESTLESSNESS, NAUSEA, AND FATIGUE\n* EFFICACY OF CARIPRAZINE IN TREATMENT OF BIPOLAR I DEPRESSION HAS BEEN DEMONSTRATED IN THREE POSITIVE PIVOTAL TRIALS\n* 53, PRIMARY AND KEY SECONDARY EFFICACY ENDPOINTS WERE MET FOR CARIPRAZINE 1.5 MG DOSE GROUP Source text for Eikon: Further company coverage:\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-03T20:21:00.000+03:00", "crawled": "2018-04-04T12:23:19.009+03:00", "highlightTitle": ""}